← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › Synthetic anticholinergics, quaternary ammonium compounds
bevonium
A03AB13
Forms & Strengths
- Tablets: 10 mg
- Oral solution: 5 mg/5 mL
Adult Dosing
- 10 to 20 mg orally three to four times daily
- Maximum daily dose: 80 mg
Pediatric Dosing
- Safety and efficacy in pediatric patients not established
- Use generally not recommended in children
Indications
- Symptomatic relief of gastrointestinal motility disorders
- Spastic conditions of the gastrointestinal tract
- Irritable bowel syndrome (IBS)
Mechanism of Action
- Synthetic quaternary ammonium anticholinergic agent
- Competitively blocks muscarinic acetylcholine receptors in the GI tract
- Relaxes smooth muscle spasm and reduces gastric secretion and motility
Contraindications
- Known hypersensitivity to bevonium or other anticholinergics
- Glaucoma (narrow-angle)
- Gastrointestinal obstruction or paralytic ileus
- Toxic megacolon
- Myasthenia gravis
- Severe urinary retention due to prostatic hyperplasia
Adverse Reactions
- Dry mouth
- Blurred vision
- Constipation
- Urinary retention
- Tachycardia
- Drowsiness and dizziness
Drug Interactions
- Enhanced anticholinergic effects when co-administered with tricyclic antidepressants, anti-histamines, or amantadine
- May alter gastrointestinal absorption of other concurrently administered oral drugs due to decreased motility
Curated Content: Needs Vetting Before Put to Clinical Use